Elevated Serum Calcium
Excess parathyroid hormone (PTH) secretion from a single parathyroid adenoma, hyperplasia of the parathyroids, parathyroid carcinoma
Especially tumors of the breast, lung, and kidney in which hypercalcemia may occur from direct bony metastasis
Multiple myeloma that directly degrades bone
Other cancers that produce hypercalcemia by inducing PTH secretion
Excess vitamin D intake
Prolonged use of diuretics and thiazides known to produce hypercalcemia
Severe hypercalcemia favors a diagnosis of cancer.
Commonly Encountered Situations
Hypercalcemia from malignancy is especially common.
Suggested Additional Lab Testing
In primary hyperparathyroidism, serum PTH is increased and serum phosphorus is decreased.
In hypercalcemia of malignancy, serum phosphorus is decreased in approximately 50% of patients, and there is a decrease in the serum PTH in these patients.
Serum protein electrophoresis is useful in the assessment for multiple myeloma. Serum 1,25-dihydroxy vitamin D is low in hypercalcemia of malignancy. It is often increased in primary hyperparathyroidism.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Do Oral Contraceptives Actually Increase Breast Cancer Risk?
- Pancreatitis and the Risk of Cancer
- FDA Approves Olaparib for BRCA-Positive Breast Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma
- PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer
- Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances